Ipatasertib

Drug Profile

Ipatasertib

Alternative Names: GCD 0068; GDC-0068; RG-7440

Latest Information Update: 24 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Array BioPharma
  • Developer Chugai Pharmaceutical; Genentech
  • Class Antineoplastics; Heterocyclic bicyclo compounds; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Proto oncogene protein c-akt inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Prostate cancer
  • Phase II Breast cancer; Gastrointestinal cancer
  • Phase I Solid tumours

Most Recent Events

  • 18 Jul 2017 Roche initiates enrolment in a phase I pharmacokinetic trial in Healthy volunteers in USA (NCT03222310)
  • 30 Jun 2017 Phase-III clinical trials in Prostate cancer (Combination therapy, First-line therapy, Hormone refractory, Metastatic disease) in Spain, Australia (PO) (NCT03072238)
  • 30 Jun 2017 Phase-III clinical trials in Prostate cancer (Combination therapy, First-line therapy, Hormone refractory, Metastatic disease) in Canada, Japan (PO) (NCT03072238)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top